Efficacy and Safety Profile of COVID-19 Vaccine in Cancer Patients: A Prospective, Multicenter Cohort Study
Ayşe İrem Yasin, Sabin Göktaş Aydın, Bilge Sümbül, Lokman Koral, Melih Şimşek, Çağlayan Geredeli, Akın Öztürk, Perihan Perkin, Derya Demirtaş, Engin Erdemoğlu, İlhan Hacıbekiroğlu, Emre Çakır, Eda Tanrıkulu, Ezgi Çoban, Melike Özçelik, Sinemis Çelik, Fatih Teker, Asude Aksoy, Sedat Tarık Fırat, Ömer Tekin, Ziya Kalkan, Orhan Türken, Bala Başak Öven, Faysal Dane, Ahmet Bılıcı, Abdurrahman Işıkdoğan, Mesut Şeker, Hacı Mehmet Türk, Mahmut Gümüş
Abstract
Aim: To compare the seropositivity rate of cancer patients with noncancer controls after inactive SARS-CoV-2 vaccination and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 noncancer volunteers. An IgG level ≥50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients. Clinical Trials Registration: NCT04771559 (ClinicalTrials.gov)